Abstract:Introduction Tyrosine kinase inhibitors (TKIs) that target epidermal growth factor receptor (EGFR) mutations are commonly administered to EGFR-positive lung cancer patients. However, resistance to EGFR-TKIs (mostly gefitinib and erlotinib) is presently a significant problem. Limited studies have focused on an EGFR-TKI resistance-related gene signature (ERS) in lung adenocarcinoma (LUAD). Methods Gefitinib and erlotinib resistance-related genes were obtained through the differential analyses of three Gene Expression Omnibus datasets. These genes were investigated further in LUAD patients from The Cancer Genome Atlas (TCGA). Patients in the TCGA-LUAD cohort were split into two groups: one for training and one for testing. The training cohort was used to build the ERS, and the testing cohort was used to test it. GO and KEGG analyses were explored for the enriched pathways between the high-risk and low-risk groups. Various software, mainly CIBERSORT and ssGSEA, were used for immune infiltration profiles. Somatic mutation and drug sensitivity analyses were also explored. Results An ERS based on five genes (FGD3, PCDH7, DEPDC1B, SATB2, and S100P) was constructed and validated using the TCGA-LUAD cohort, resulting in the significant stratification of LUAD patients into high-risk and low-risk groups. Multivariable Cox analyses confirmed that ERS had an independent prognostic value in LUAD. The pathway enrichment analyses showed that most of the genes that were different between the two risk groups were related to the immune system. Further immune infiltration results revealed that a lower immune infiltration score was observed in high-risk patients, and that various leukocytes were significantly related to the ERS. Importantly, samples from the high-risk group showed lower levels of PD-1, PD-L1, and CTLA-4, which are important biomarkers for immunotherapy responses. Patients in the high-risk group also had more gene mutation changes and were more sensitive to chemotherapy drugs like docetaxel and sorafenib. The ERS was also validated in the GSE30219, GSE11969 and GSE72094, and showed a favorable prognostic value for LUAD patients. Discussion The ERS established during this study was able to predict a poor prognosis for LUAD patients and had great potential for predicting drug responses.

High Expression Of Erbb Family Members And Their Ligands In Lung Adenocarcinomas That Are Sensitive To Inhibition Of Epidermal Growth Factor Receptor

Aberrant Epidermal Growth Factor Receptor Signaling And Enhanced Sensitivity To Egfr Inhibitors In Lung Cancer

A Novel Acquired EGFR-SEPT14 Fusion Confers Differential Drug Resistance to EGFR Inhibitors in Lung Adenocarcinoma.

Epidermal growth factor receptor mutations in lung cancer

Diversity of epidermal growth factor receptor-mediated activation of downstream molecules in human lung carcinomas

EGFR Overexpression and Mutations Lead to a Change in Biological Characteristics of Human Lung Adenocarcinoma Cells

Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells

Functional Analysis of Receptor Tyrosine Kinase Mutations in Lung Cancer Identifies Oncogenic Extracellular Domain Mutations of Erbb2

Identification of a novel gene signature of lung adenocarcinoma based on epidermal growth factor receptor-tyrosine kinase inhibitor resistance

Acquired Resistance of Lung Adenocarcinoma to EGFR-tyrosine Kinase Inhibitors Gefitinib and Erlotinib

Expression of EGFR and RAS/MAPK signal pathway-related proteins and their significance in lung adenocarcinoma

Cellular Origins of EGFR‐Driven Lung Cancer Cells Determine Sensitivity to Therapy

Targeting epidermal growth factor receptor: Central signaling kinase in lung cancer

How Sensitive Are Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor for Lung Adenosquamous Cell Carcinoma Harboring EGFR Mutation? A Bicenter Research and Pooled Analysis of Published Reports.

Association Between EGFR/KRAS Mutation and Expression of VEGFA, VEGFR and VEGFR2 in Lung Adenocarcinoma

The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells

Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells.

Disease-related cellular protein networks differentially affected under different EGFR mutations in lung adenocarcinoma

Concurrent Epidermal Growth Factor Receptor T790M Secondary Mutation and Epithelial‐mesenchymal Transition in a Lung Adenocarcinoma Patient with EGFR‐TKI Drug Resistance

Hypoxia‐inducible Factor‐1α and Nuclear Factor‐κb Play Important Roles in Regulating Programmed Cell Death Ligand 1 Expression by Epidermal Growth Factor Receptor Mutants in Non‐small‐cell Lung Cancer Cells

Egfr Exon 19 Insertions: A New Family of Sensitizing Egfr Mutations in Lung Adenocarcinoma